Editorially reviewed by Dr Fatimah Khan, registered with the Pakistan Medical and Dental Council (PMDC no. 104595-P). Editorial medical reviewer; does not prescribe or review patient assessments.
Review details
Review recorded:
Review scope: This article edition.
Editorial reviewer for Prescrivia. Editorial review does not establish participation in patient consultations.
Clinical review does not replace individual medical advice. Prescrivia is a technology intermediary; independent doctors make clinical decisions.
Legal review: Qualified review pending.
Language review: Qualified review pending.
Source and review
Source published:
Attributed source update:
Text edited:
Editorial role: Editorial team. This description does not establish an individual credential or clinical review of this edition.
Read our editorial policy and corrections. Edit dates and source descriptions do not establish qualified review.
What is terbinafine used for?
Terbinafine is an antifungal medicine. Topical products are used for some fungal skin infections, while tablets may be used for appropriate nail or other fungal infections after assessment. A changed nail or itchy rash does not establish a fungal diagnosis.
Cream, spray, special film-forming solution and tablets have different instructions. A single-application product's directions should not be applied to an ordinary cream.
Diagnosis comes before a tablet course
Nails can change because of trauma or other skin disease. A clinician may need a nail sample before deciding whether tablets are appropriate. The infection site, suspected organism and your health affect the choice.
It is too broad to say that all fungal nails need tablets. The extent and diagnosis matter, and a clinician may recommend another option.
The UK 250 mg tablet product cited below is a specific example, not proof that every formulation, age group or country uses an identical regimen.
How long does treatment take?
For appropriate nail infections, that UK tablet information describes typical courses of six weeks for fingernails and twelve weeks for toenails, with individual exceptions. Follow the prescribed duration and review plan.
A treated nail can still look abnormal when the tablet course finishes because healthy nail must grow out. NHS information notes that recovery of appearance can take months. There is no universal date when a nail will look fully normal.
Finish the prescribed course unless a clinician advises stopping or a serious reaction requires urgent action. Do not continue tablets beyond the prescribed course simply because the nail still looks abnormal. Equally, do not stop early just because symptoms improve.
Ask for reassessment if the diagnosis, response or recurrence is uncertain rather than restarting leftover tablets.
Liver monitoring with oral treatment
The cited UK tablet information advises liver-function testing before treatment and periodic monitoring, with a check after four to six weeks. Chronic or active liver disease is an important restriction for oral treatment.
If symptoms suggesting liver injury occur—such as persistent nausea, loss of appetite, unusual tiredness, jaundice, dark urine or pale stools—stop the tablets and seek medical advice immediately. Testing and review should be arranged by the treating professional.
Topical exposure differs, but that does not make topical products appropriate for every rash or exclude local reactions.
Other safety questions
Tell the prescriber about other medicines, kidney or liver problems, pregnancy, breastfeeding and previous reactions. Read the exact leaflet for interactions and serious skin or taste-related reactions.
For topical use, follow that product's site, frequency and course instructions. Avoid treating an uncertain rash indefinitely. A worsening rash, significant inflammation or an unexpected reaction needs professional advice.
Information and clinical decisions
This guide provides general information, not a diagnosis or personal treatment plan. Any clinical assessment and prescribing decision rests with an independent clinician. Prescrivia is a technology intermediary, not a medical provider or pharmacy; it does not prescribe, sell or dispense medicines. Assessment does not guarantee a prescription, medicine availability or a health outcome.
Further reading: treatment information.
Read about online consultations and their limits. Service information must not delay urgent local care.
Sources
- UK terbinafine 250 mg tablet product information — Oral indication/course context, chronic/active liver restriction and baseline plus four-to-six-week liver monitoring.
- UK terbinafine tablet patient leaflet — Product-specific course duration and stop/seek-advice symptoms for liver injury and other reactions.
- NHS: terbinafine common questions — Difference between treatment response and slow nail regrowth, and formulation-dependent use.
See the current clinical, legal and language review statuses for this edition. Source checks are editorial work, not approval.